ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Viral arthritis: Causes and approach to evaluation and management

Viral arthritis: Causes and approach to evaluation and management
Literature review current through: Jan 2024.
This topic last updated: Oct 04, 2023.

INTRODUCTION — Arthritis and arthralgias are commonly associated with viral infections (table 1) [1-3].

This topic will provide an overview of the causes, the clinical presentation, and a general approach to evaluation and management of these disorders. The evaluation of polyarticular pain in adults is discussed separately. (See "Evaluation of the adult with polyarticular pain".)

CAUSES — Viruses can initiate joint and other rheumatologic symptoms by a variety of mechanisms, including direct invasion of the joint cells or tissues, immune complex formation, and immune dysregulation. These mechanisms depend upon host factors, including age, sex, genetics, infectious history, and the immune response [4-8].

Many viruses can cause arthralgias and arthritis, although the relative prevalence of specific viruses has evolved. For example, chronic persistent viruses such as hepatitis B, hepatitis C and human immunodeficiency virus (HIV) are becoming less prominent causes of viral arthritis due to vaccinations, pre-exposure prophylaxis, and advances in antiviral therapies. However, other viral infections such as Zika, chikungunya, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are becoming increasingly important [9].

Parvovirus

Children – Arthritis or arthralgias are relatively uncommon in children [10]. In children, parvovirus B19 is best known for causing the common childhood illness erythema infectiosum. In children (and less commonly, adults), parvovirus B19 infection can also present as a nonspecific febrile illness with a systemic autoimmune rheumatic disease-like syndrome [11,12].

Adults – Parvovirus B19 should be considered in any adult presenting with recent-onset polyarthralgias or polyarthritis.

Arthritis or arthralgias occur in over half of infected adults [10]. In adults, arthralgias or arthritis occur during the acute phase of infection. Arthralgias are more frequent than arthritis; both are more common in females than in males.

Like rheumatoid arthritis, parvovirus B19 affects small joints (including the interphalangeal joints and wrists) in an additive fashion and is associated with prominent morning stiffness. A variety of auto-antibodies may be transiently positive during infection including antinuclear antibodies, rheumatoid factor, anti-double stranded deoxyribonucleic acid (DNA) and antiphospholipid antibodies. Their presence may lead the clinician to overlook the possibility of an underlying viral infection.

The joint symptoms may persist for weeks to months prior to resolution, and recurrent arthritis has been reported [13].

Parvovirus B19 may cause a viral arthritis through direct infection of the joint and immune complex formation [13].

Nonarticular manifestations of parvoviral infection are discussed in more detail elsewhere. (See "Clinical manifestations and diagnosis of parvovirus B19 infection".)

Alphaviruses (including chikungunya) — Arthritis is a common feature of many alphavirus infections.

Alphaviruses are one of the main genera of arboviruses (transmitted via arthropod) that cause arthritis. Starting in the early 2000s, there has been an epidemic shift of arboviral infections (especially chikungunya) from the tropics to the Western Hemisphere, prompting rheumatologists and other practitioners to need to consider these infectious etiologies in returning travelers with joint pain. Alphavirus infections may cause joint symptoms mainly through an immune complex reaction induced by virus persisting in synovial macrophages [14].

Alphaviruses are single-stranded, positive-sense ribonucleic acid (RNA) viruses in the family Togaviridae and are often divided into "Old World" and "New World." "Old World" alphaviruses are typically associated with arthritis, while "New World" are associated with encephalitis [15].

There are seven alphaviruses associated with viral arthritis:

Chikungunya virus – Chikungunya was previously found mainly in South and East Asia, Africa, and the Western Pacific, with recurrent epidemics with as many as 40,000 involved in Thailand in 1962 [16-18]. It has subsequently become a much more global disease with increasing world travel and global warming, with increasing arthritic symptoms including large outbreaks in Italy, India, and Indian Ocean islands as well as reports from islands in the Caribbean since 2013 [19]; subsequently, local transmission was confirmed in many countries and territories in the Caribbean region and in North, Central, and South America [20-22]. Chikungunya fever and the musculoskeletal manifestations of the infection are described in detail separately, as are approaches to the treatment of affected patients and the prevention of infection. (See "Chikungunya fever: Epidemiology, clinical manifestations, and diagnosis" and "Chikungunya fever: Treatment and prevention".)

Ross River virus and Barmah Forest virus – Ross River virus affects as many as 8000 Australians annually, and the Barmah Forest virus, also found in Australia and Pacific islands, causes approximately 500 to 1500 symptomatic infections per year. These infections are described in more detail separately. (See "Ross River virus infection" and "Potential health hazards in travelers to Australia, New Zealand, and the southwestern Pacific (Oceania)", section on 'Arboviral infections'.)

Sindbis virus – Sindbis virus was first isolated in Egypt and is linked to Pogosta disease (Finland), Ockelbo disease (Sweden) and Karelian fever (Russia), manifesting with arthritis and rash [17,23].

Mayaro virus – The Mayaro virus, constituting another group, is found mainly in South America and occurs in small sporadic epidemics, causing arthritis and fever [17,24].

O'nyong'nyong – O'nyong'nyong is found in Central and East Africa with occasionally small epidemics; however, more than two million people were affected in an epidemic from 1959 to 1962 [17,25]. The clinical presentation is similar to that of chikungunya, with polyarthritis, fever, and rash.

Igbo-Ora virus – Igbo-Ora, considered as a separate group, is a virus related to O'nyong'nyong and found mainly in Central Africa, with an outbreak in 1988 [17]. Infection is typically associated with a triad of fever, arthritis, and rash [16].

A unique and characteristic feature of these alphaviruses is that they essentially always cause arthritis [26]. Most of these viruses also cause fever, rash, and myalgias. The rash occurs several days after the onset of joint symptoms and is short-lived, involving the face, trunk, and flexor surface of the extremities. Mild lymphadenopathy, mild leukopenia, and lymphocytosis may be present.

The onset in chikungunya and o'nyong'nyong infections is abrupt with fever and joint symptoms and can be severe in nature [17,27,28]. The other alphaviruses are associated with a more gradual onset of fever and nonspecific constitutional symptoms prior to joint involvement [16].

In most patients, the arthritis progressively resolves over an average of a three- to six-month period. However, the Ross River virus and chikungunya may lead to a persistent arthritis [29-31], with chikungunya arthritis persisting beyond six months in up to half of those infected, and a much smaller proportion go on to develop a chronic inflammatory arthritis with clinical features resembling rheumatoid arthritis.

While alphaviruses like chikungunya and to some degree Ross River have been more heavily studied, most remain endemic to tropical areas and are not as well researched.

Flavivirus

Zika virus – Clinical manifestations of Zika virus infection include fever, rash, headache, arthralgia, myalgia, and conjunctivitis, although asymptomatic infection is common. Among those with symptoms, arthralgia are characteristic, particularly of the small joints of the hands and feet, but true arthritis has not been reported [32]. Arthralgias, along with the extraarticular symptoms, usually resolve within two to seven days. (See "Zika virus infection: An overview".)

Dengue virus – The classic findings of dengue virus infection are an acute febrile illness with headaches and marked muscle and joint pain, leading to the moniker "break-bone fever" [33]. Arthralgias occur in 60 to 80 percent of patients. Leukopenia and thrombocytopenia may be present, and liver enzymes may be elevated [34]. Most cases are mild, but a small percentage of patients have potentially lethal forms called dengue hemorrhagic fever and dengue shock syndrome [35]. (See "Dengue virus infection: Clinical manifestations and diagnosis".)

Hepatitis viruses

Hepatitis A virus — True arthritis, rather than arthralgias alone, is extremely rare in patients with hepatitis A virus (HAV) infection.

Arthralgias and rash occur in 10 to 14 percent of patients infected with hepatitis A, most often during the prodromal period. Patients with joint manifestations usually present with knee and ankle arthralgias and an accompanying rash. The arthritis is self-limited and does not become chronic. (See "Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis", section on 'Extrahepatic manifestations' and "Overview of hepatitis A virus infection in children", section on 'Clinical manifestations'.)

Arthritis has been described in case reports primarily in patients with vasculitis who had a chronic relapsing form of hepatitis A and also high titer of polyclonal immunoglobulin G (IgG)- and IgM-circulating cryoglobulins (type III cryoglobulinemia) [36].

Overviews of HAV infection are presented separately. (See "Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis" and "Overview of hepatitis A virus infection in children".)

Hepatitis B virus — Arthritis is more commonly associated with acute, rather than chronic, hepatitis B virus (HBV) infection.

Acute HBV infection – Ten to 25 percent of patients with acute HBV develop arthritis, typically during the prodromal stage of the disease, prior to the onset of jaundice [37].

The arthritis may mimic rheumatoid arthritis, presenting with an additive, symmetric, small joint arthritis associated with morning stiffness and rheumatoid factor positivity [38]. However, the arthritis can also be migratory and may affect the large joints [37,39,40].

The arthritis most often occurs in young adults, more often in females than in males. An urticarial or maculopapular eruption primarily involving the lower extremities commonly appears at the same time as the arthritis [37,40].

The arthritis persists for days to weeks and commonly resolves with the onset of jaundice [37,40]. The arthritis is always self-limited and does not lead to a chronic arthritis or erosive joint damage [41,42].

Chronic HBV infection – Arthralgias/arthritis are uncommon in patients with chronic HBV infection. When present, they are generally accompanied by myalgias.

When arthritis does occur, it generally appears in association with HBV-associated polyarteritis nodosa, a diagnosis that has become increasingly uncommon. Other manifestations of immune complex-mediated disease may be present, such as glomerulonephritis [43] and essential mixed cryoglobulinemia [44]. Such manifestations have become much less common with the availability of more aggressive and targeted treatment of the infection [39]. (See "Clinical manifestations and diagnosis of polyarteritis nodosa in adults", section on 'Clinical features'.)

The clinical manifestations, diagnosis, and management of HBV infection are described in detail separately. (See "Hepatitis B virus: Clinical manifestations and natural history" and "Hepatitis B virus: Screening and diagnosis in adults".)

Hepatitis C virus — Arthralgia and myalgia have frequently been reported in patients with hepatitis C virus (HCV) infection, mostly in the context of mixed cryoglobulinemic vasculitis. Frank arthritis is rare; when it does occur, there is no evidence of joint destruction.

Acute HCV infection – Arthralgias have been reported in 25 percent of patients with acute HCV infection [45]. Arthritis is extremely rare.

Chronic HCV infection – Chronic HCV infection is associated with a broad spectrum of extrahepatic manifestations; however, arthritis is rare. It should be noted that over half of patients with chronic HCV will have detectable circulating cryoglobulins, but fewer than 5 percent develop symptoms related to mixed cryoglobulinemia (eg, arthritis, purpura, polyneuropathy, glomerulonephritis). Tests for rheumatoid factor, antinuclear antibodies, and anti-SSA antibodies are frequently positive but are not associated with a rheumatic disease.

Direct-acting antivirals have made HCV-associated mixed cryoglobulinemia much less common and have become the treatment of choice for patients presenting with extrahepatic manifestations [46,47].

The clinical manifestations, diagnosis, and management of the mixed essential cryoglobulinemic vasculitis and chronic hepatitis C are discussed in detail separately. (See "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis" and "Mixed cryoglobulinemia syndrome: Treatment and prognosis".)

Rubella and rubella vaccine virus — Rubella and rubella vaccine virus are associated with a high incidence of arthritis.

Rubella virus – The onset of joint symptoms due to rubella virus is typically abrupt, occurring in most patients within a one-week period before and after the characteristic rash [48,49].

The pattern of joint involvement may be symmetric, migratory, or additive, with resolution of most joint symptoms within two weeks [49-51]. The small joints of the hands, wrists, and knees are most commonly involved. Arthralgias are much more common than arthritis; however, there is often considerable pain and swelling in the soft tissues surrounding the joint as well as synovial tendon sheath involvement, occasionally leading to tenosynovitis and carpal tunnel syndrome [49-51].

In one report, rates were as high as 30 percent of females and 6 percent of males with rubella infection [48]. Joint symptoms may rarely persist as long as a year. However, chronic joint damage does not occur [50,51]. Recurrence of joint symptoms is uncommon.

Rubella virus infection and its complications are described in detail separately. (See "Rubella".)

Rubella virus vaccine

Children – Transient arthralgias may develop approximately 7 to 21 days after vaccination with rubella virus vaccine [49,52]. Arthralgias, usually of small peripheral joints, have been reported in 0.5 percent of young children. Recurrence occurs in approximately 1.3 percent of patients with arthralgias [53].

Adults – Arthralgias occur in 25 percent of adults and postpubertal adolescents following rubella vaccination, and 10 percent develop arthritis, which is also transient [54]. One study showed that the risk of arthritis following rubella vaccination may be higher in females who have very low prevaccine levels of neutralizing antibodies [55].

Both rubella and rubella virus vaccine may directly infect the synovium, although isolation of virus from the joint is uncommon [49,56-60].

The adverse effects of rubella vaccination are described in detail separately. (See "Measles, mumps, and rubella immunization in adults", section on 'Adverse effects' and "Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'Adverse effects'.)

Human immunodeficiency virus infection — HIV infection has been associated with several rheumatic disease syndromes, although advances in screening and treatment is making it less common as a cause of rheumatic disease [61-64]. A combination of immunodeficiency, immune hyperactivity, dysregulated production or activity of cytokines, and molecular mimicry may contribute to the rheumatic manifestations of HIV infection [61].

Epidemiologically, antiretroviral therapy has made the syndromes discussed below much less common. However, HIV is still underdiagnosed and undertreated, making it important to consider these syndromes in the appropriate clinical setting.

HIV-related joint conditions — Several conditions affecting the joints appear to be HIV-specific:

Arthralgia/arthritis associated with acute infection – Patients newly infected with HIV may experience an infectious mononucleosis-like syndrome that includes arthralgias and myalgias, among the other findings [63,65]. Joint pain most often involves the knees, shoulders, and elbows. A symmetric "viral polyarthritis" has also been reported [63]. These symptoms are self-limited, usually lasting for two weeks.

Painful articular syndrome – Patients with chronic HIV infection may develop the painful articular syndrome, which is a self-limited disorder lasting for less than 24 hours in patients that causes severe arthralgias but not arthritis [62]. The pain is excruciating and debilitating. It is associated with later stages of infection and is reported in up to 10 percent of African patients with HIV and some other groups, but not in all case series [63]. Bone and joint pain is noted, especially in the lower extremities in an asymmetric pattern, which is out of proportion to clinical findings, often requiring hospitalization and even opioids to manage pain. The etiology is not known and treatment is symptomatic.

HIV-associated arthritis – Patients at any stage of HIV illness can develop an HIV-associated arthritis, which is a self-limited nondestructive arthritis, usually lasting less than six weeks [66,67]. The prevalence ranges from 0.4 to 13.8 percent [68] and has a male preponderance. Joints of the lower extremity are usually involved in an asymmetric, oligoarticular pattern. Synovial fluid is inflammatory. Rarely, a more prolonged course with joint destruction has been noted [62].

HIV impact on non-HIV rheumatic disorders — With the widespread use of combination antiretroviral therapy, arthritis in a patient with HIV is more likely due to a concomitant rheumatic disease than HIV. Patients with both HIV and a rheumatic disease can be challenging to treat.

Reactive arthritis – Reactive arthritis (the primary form of spondyloarthritis seen in patients with HIV) was first described in 1987, in 13 patients with acquired immunodeficiency syndrome (AIDS) and severe oligoarticular arthritis with features of reactive arthritis [69]. The prevalence in people with HIV ranges from 1.7 to 11.2 percent [70]. Human leukocyte antigen B27 (HLA-B27) is positive in roughly 70 percent of White patients with HIV-associated reactive arthritis [71]. A similar association is not seen in Black African patients. This reactive arthritis is thought to be associated with late stages of immunosuppression (eg, uncontrolled HIV).

The classic triad of arthritis, urethritis, and conjunctivitis is not common; rather, an incomplete form of reactive arthritis usually occurs [72]. Axial involvement and uveitis are uncommon in HIV-associated spondyloarthritis [62]. Mucocutaneous disease, including keratoderma blennorrhagicum, circinate balanitis, and psoriaform skin disease is often present, especially in patients with HIV and a positive HLA-B27, who tend to have worse disease outcome [73].

In sub-Saharan Africa where HIV is highly prevalent, HLA-B27-associated spondyloarthritis is rare. Other genetic factors such as HLA-B*5703 have been noted in patients with HIV and spondyloarthritis in Zambia [74]. The clinical manifestations of reactive arthritis in patients with HIV are similar to those in other populations. (See "Reactive arthritis".)

Reactive arthritis in HIV is clinically distinguished from HIV-associated arthritis in its chronicity and relapsing nature, by the presence of enthesopathy and mucocutaneous manifestations, and by HLA-B27 positivity [75], though multiple joint involvement has been reported in cases of septic arthritis caused by Salmonella species. (See "Septic arthritis in adults".)

Psoriatic arthritis – The prevalence of psoriatic arthritis (PsA) in patients with HIV is 1 to 2 percent, similar to that in patients without HIV; the severity is often worse in HIV patients, especially those not being treated with antiretroviral therapy [76]. The most commonly and most severely affected joints are generally those of the feet and ankles. As with reactive arthritis, frank synovitis is unusual and enthesitis may be a disabling clinical feature. Axial involvement may occur and be associated with radiographic changes of sacroiliitis [61]. Peripheral joint radiographs may reveal "pencil in cup" deformities and osteolysis similar to those seen with classic PsA, and these may be present in the absence of frank psoriatic skin involvement (ie, PsA sine psoriasis). (See "Treatment of psoriatic arthritis".)

Two forms of PsA have been reported in patients with HIV. The first is a sustained and aggressive type of arthritis leading to joint erosion, and the second is a more mild and intermittent pattern of joint involvement. There is a strong association of HLA-B27 with pustular psoriasis and PsA in HIV patients [76].

Immune reconstitution inflammatory syndromes – New autoimmune or inflammatory disease or flares of preexisting disease, such as sarcoidosis or rheumatoid arthritis-like illnesses, have been reported in association with reconstitution of T-cell-mediated immunity [77]. Adult-onset Still's disease has also been reported, as have a number of autoimmune but nonrheumatologic disorders. The pathogenesis and features of the immune reconstitution inflammatory syndromes (IRIS) seen in some patients with restitution of immune function are described in detail separately. (See "Immune reconstitution inflammatory syndrome".)

Other viral etiologies

Mumps virus – Arthritis is uncommon in patients with mumps, with fewer than 100 cases reported in the literature. Mumps is characterized by parotitis, which is usually bilateral and follows a short prodromal phase with nonspecific constitutional symptoms. However, some symptomatic patients do not have parotitis [78,79].

If present, the arthritis typically occurs after the onset of parotitis. A migratory polyarthritis involving both large and small joints is the most common presentation, but polyarthralgias or a monoarthritis can also occur [78,79]. Low-grade fever typically accompanies the joint symptoms, which generally resolve over a period of weeks. No long-term joint damage has been reported. The mechanism by which mumps virus gives rise to joint symptoms is not known. The general features of mumps are discussed elsewhere. (See "Mumps".)

Adenovirus infection – Adenoviruses comprise a large family of immunotypes with a wide range of clinical illnesses. Only a small number of cases of adenovirus-associated arthritis have been reported [80]. Affected patients typically present with mild fever, nonspecific constitutional symptoms, arthralgias, arthritis mainly of the knees, and rash. The disease is typically self-limited but may persist over a year in some cases [80]. (See "Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection" and "Diagnosis, treatment, and prevention of adenovirus infection".)

Herpesvirus infections – A number of arthritis syndromes may be associated with the herpesvirus family. Epstein-Barr virus (EBV) is the most common cause of arthralgias and arthritis of this group, but the other members of this family, including varicella-zoster virus, herpes simplex virus, and cytomegalovirus, may infrequently also cause joint symptoms.

Epstein-Barr virus – Approximately 90 percent of patients newly infected with EBV, the primary agent of infectious mononucleosis, are asymptomatic. Of the 10 percent with symptoms, the majority have arthralgias; true arthritis is less common [81,82].

Arthralgias are the most common joint findings, with occasional large-joint swelling, and arthrocentesis may reveal an inflammatory joint fluid [78,81]. The joint complaints usually occur in the first weeks of the infection and can be acute in nature. Overall, the joint signs and symptoms are self-limited [81,83]. Epstein-Barr viral infections have been implicated in complicating treatment of juvenile idiopathic arthritis, especially for patients on biologic response modifiers [82]. Awareness of a past or present EBV infection may help in determining treatment options [82].

The clinical manifestations, diagnosis, and management of EBV infection are described in detail separately. (See "Virology of Epstein-Barr virus" and "Clinical manifestations and treatment of Epstein-Barr virus infection" and "Infectious mononucleosis".)

Varicella – Arthritis associated with chickenpox (varicella) is a rare but well-described phenomenon that occurs within several days of the onset of the rash [84,85]. Monoarticular knee involvement is most common, with swelling, pain, and limitation of motion. However, the pain is thought to be due to viral involvement of the nerve root, rather than the joint itself. (See "Clinical features of varicella-zoster virus infection: Chickenpox".)

Herpes simplex virus – Arthritis associated with herpes simplex virus has been reported in a few occasions, all associated with a generalized herpes simplex virus type 1 infection [86,87]. In most cases, the disease is self-limited, resolving in 10 days to three months. (See "Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection".)

Cytomegalovirus – Cytomegalovirus arthritis is rare, but severe cytomegalovirus polyarthritis has been described in several immunocompromised bone marrow transplant recipients [78,86]. These patients had painful, warm, swollen knees, and joint aspiration yielded a noninflammatory synovial fluid; joint symptoms persisted for several months. Acute arthralgias have also been reported in renal transplantation patients with cytomegaloviral infections [78,88,89]. (See "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults" and "Approach to the diagnosis of cytomegalovirus infection" and "Overview of cytomegalovirus infections in children".)

Coronavirus – Coronavirus is not usually associated with rheumatologic symptoms; however, SARS-CoV-2 infections has rarely been associated with a post-reactive arthritis that responded to nonsteroidal antiinflammatory drugs (NSAIDs) [90]. Also, arthralgias have been noted in children with multisystem inflammatory syndrome (MIS-C) [91]. (See "COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis".)

Enterovirus – Arthritis occurs in only 0.1 percent of patients infected with enterovirus [1-3]. The arthritis occurs simultaneously with other symptoms of acute viral infection, including fever, sore throat, pleuritic pain, myocarditis, and rash. Both large and small joints may be involved. Routine laboratory findings are nonspecific and include leukocytosis, elevated erythrocyte sedimentation rate, and synovial fluid white blood cell counts ranging from 2000 to >10,000/mm3.

The incubation period for viral infection is short (ie, three to five days) and is followed by the abrupt onset of fever, headache, and other nonspecific constitutional signs and symptoms. There may be associated maculopapular rash, pharyngitis, conjunctivitis, myalgias, nausea, vomiting, diarrhea, and abdominal pain. Symptoms are generally short-lived (ie, two to four days), although they may recur [92]. Enterovirus may cause arthritis through direct infection of the joint [1]. (See "Enterovirus and parechovirus infections: Epidemiology and pathogenesis" and "Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention".)

COMMON CLINICAL FEATURES — There is no single presentation that is typical of a viral arthritis; however, in general, common features include:

Sudden-onset polyarthritis

Self-limited duration

Lack of erosive joint damage

Travel history to endemic location

Concomitant fever, constitutional symptoms, or viral exanthem.

An arthritis may precede other signs of viral infection (eg, before icterus in hepatitis B virus [HBV] infection).

Specific features of the different viruses that cause arthritis are discussed elsewhere. (See 'Causes' above.)

EVALUATION AND DIAGNOSIS

Acute arthritis

Establish the presence of arthritis — Arthralgias (ie, the subjective complaint of joint pain) are a common feature of many viral infections. However, only a subset of viruses can cause a true arthritis (which is associated with objective evidence of synovial hypertrophy and inflammation).

Symptomatology alone is not adequate to establish a diagnosis of arthritis. Diagnosing a polyarthritis requires a joint examination of the upper and lower extremities to look for evidence of synovitis.

If a full musculoskeletal examination is not possible, screening patients for diminished grip strength may help identify patients with an early polyarthritis [93]. Subclinical joint inflammation and tenosynovitis in the hand joints causes diminished grip strength, which may be easier to detect than true synovitis.

The joint examination in patients with suspected arthritis is discussed in more detail elsewhere. (See "Evaluation of the adult with polyarticular pain", section on 'Joint examination'.)

When to suspect viral etiology — We suspect a viral arthritis in a patient presenting with an acute (eg, less than four weeks) polyarthritis associated with recent travel, sick contacts, or clinical evidence of a viral infection (eg, rash and/or fever) (algorithm 1).

An acute monoarthritis is unlikely to be caused by a viral infection. In children, varicella can rarely cause an acute monoarthritis. Patients presenting with an acute monoarthritis should also be evaluated for nonviral etiologies, such as a crystalline or septic arthritis. (See "Clinical manifestations and diagnosis of gout" and "Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition (CPPD) disease" and "Septic arthritis in adults".)

Among patients with suspected viral arthritis, certain features may be suggestive of particular viral etiologies (see 'Causes' above):

Arthritis – A true arthritis is commonly associated with acute and chronic hepatitis B virus (HBV), chronic hepatitis C virus (HCV), parvovirus B19, rubella, alphaviruses (eg, chikungunya), flaviviruses (eg, Zika), and HIV infection.

Extra-articular physical findings – Characteristic rashes may be associated with rubella, parvovirus B19, and varicella. Parotid enlargement may be found with mumps. Palpable purpura or other evidence of vasculitis may be associated with viral hepatitis.

Laboratory tests – Elevated transaminase levels and hyperbilirubinemia occur with viral hepatitis but can also be a nonspecific finding in other viral infections. An anemia with a low reticulocyte count may be caused by parvovirus B19 infection. Viral hepatitis and parvovirus B19 frequently cause positive auto-antibodies (eg, antinuclear antibodies, rheumatoid factor, etc).

Travel – Alphaviruses and flaviviruses have geographic distributions specific to each species. (See 'Other viral etiologies' above.)

Pattern of joint involvement – A migratory arthritis may be indicative of hepatitis B virus or rubella, although an additive pattern is more common. An acute monoarthritis may rarely be found with varicella infection or chronic hepatitis B.

Comorbidities – Cytomegalovirus may cause an arthritis in immunocompromised patients. HIV is associated with multiple joint manifestations, both directly and indirectly.

Vaccination status – Many vaccinations are associated with transient arthralgias. Rubella vaccine is associated with a high incidence of arthritis. Vaccination against hepatitis B, rubella, or SARS CoV-2 makes these etiologies less likely to cause a viral arthritis.

Laboratory findings (including synovial fluid analysis) are generally of little value in differentiating viral arthritis from other musculoskeletal conditions, unless characteristic findings of another disorder are present.

Limited role for diagnostic testing — We do not suggest a standard panel of tests for all patients presenting with an acute viral arthritis. Acute viral arthritis is most commonly caused by a self-limited viral infection and by itself is not an indication for extensive testing. In these cases, the diagnosis of viral arthritis is made indirectly when the diagnosis of the systemic infection is made (see below). The approach to the diagnoses of these infections is discussed in dedicated topic reviews.

Indications for additional testing – Specific diagnostic testing may be indicated when the arthritis is part of a viral syndrome that raises suspicion for a particular etiology that has management or public health implications. This includes acute or chronic HIV infection; viral hepatitis; and rubella, mumps, or varicella virus infection. Additionally, it is reasonable to screen adult patients at least once for hepatitis B, hepatitis C, and HIV, and more frequently if risk factors are present.

Caveats for serologic testing – In some cases, diagnostic testing for the viral infection is based on serologic testing. However, IgG antibodies may be present due to a prior exposure unrelated to the current illness. This is a particular problem with parvovirus and enterovirus, which are endemic in many populations. Similar considerations apply to alphaviruses (such as Barmah Forest, Ross River, chikungunya, Mayaro, and Sindbis virus) in regions where these infections are endemic. In such cases, a positive IgM antibody or an increase in IgG titers greater than fourfold between the acute and convalescent period suggest that the infection is recent.

Limited role for synovial fluid tests – Isolation of a virus directly from synovial fluid or tissue is not a common clinical practice and has not been well validated for clinical use. Similarly, polymerase chain reaction (PCR)-based tests are unreliable for identifying the etiology of a viral arthritis. PCR has predominantly been used to identify specific bacteria (but not viruses) in patients with culture-negative periprosthetic joint infection [94]. PCR of synovial fluid and tissue from patients with inflammatory arthritis may identify multiple viruses that have a tropism for inflamed synovial tissue but are not pathogenic [95]. These viruses include cytomegalovirus, parvovirus B19, Epstein-Barr virus (EBV), and herpes simplex virus. A positive synovial specimen PCR in such cases is not necessarily indicative of a viral arthritis.

Diagnosis — The diagnosis of an acute viral arthritis is made clinically, based on the clinical presentation (see 'When to suspect viral etiology' above). The diagnosis is made presumptively in a patient presenting with an acute arthritis with a concurrent viral infection and is clinically supported by resolution of symptoms in a few weeks (algorithm 1). If the arthritis persists, additional evaluation is warranted. (See 'Chronic arthritis' below.)

Chronic arthritis — Viral infection rarely leads to a chronic arthritis. Therefore, in most cases, extensive testing and workup for such cases is unnecessary in most patients. Most chronic arthritis is due to a rheumatic illness (eg, rheumatoid arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus). (See 'Differential diagnosis' below.)

An important exception is chikungunya-related arthritis, which may mimic more serious and persistent forms of noninfectious arthritis, with almost half of patients still having joint symptoms six months after start of infection. This should be suspected in patients who have relevant epidemiology (ie, travel to an endemic area) related to the onset of symptoms. The evaluation and diagnosis of chikungunya is discussed elsewhere. (See "Chikungunya fever: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'.)

Rubella virus, parvovirus, EBV, and other alphaviruses may rarely induce a persistent arthritis in some patients, but these forms of chronic arthritis are uncommon [13,58-60,96-98].

DIFFERENTIAL DIAGNOSIS — Arthritis that persists for longer than six weeks without improvement requires consideration of alternate diagnoses. There are multiple other causes of polyarticular joint pain, particularly rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritis, and juvenile idiopathic arthritis, all of which may be difficult to distinguish from a viral arthritis early in the disease course (table 2). With time, these alternate diagnoses tend to develop pathognomic features that help confirm the clinical diagnosis (table 3). Immunodeficiencies may also present with arthralgias and arthritis. In some cases, the correct diagnosis may be apparently only in retrospect, after observing the clinical course and response to therapy over several months. The differential diagnosis and evaluation of polyarticular pain and polyarthritis are reviewed in detail separately:

Evaluation of polyarticular pain (see "Evaluation of the adult with polyarticular pain")

Diagnosis of rheumatoid arthritis (see "Diagnosis and differential diagnosis of rheumatoid arthritis")

Diagnosis of systemic lupus erythematosus (see "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults")

Diagnosis of spondyloarthritis (see "Clinical manifestations and diagnosis of peripheral spondyloarthritis in adults")

Diagnosis of juvenile idiopathic arthritis (see "Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis")

Clinical manifestations of common variable immunodeficiencies (see "Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults")

MANAGEMENT — Most viral arthridities are self-limited. Therefore, the treatment of viral arthritis is generally supportive.

Supportive care — We suggest treatment with analgesic agents (eg, acetaminophen) and nonsteroidal antiinflammatory drugs (NSAIDs) in doses typically used in any inflammatory arthritis (table 4), such as rheumatoid arthritis. (See "Initial treatment of rheumatoid arthritis in adults", section on 'NSAIDs'.)

Aspirin should be avoided in children and young adults, given the association between aspirin and Reye syndrome. (See "Acute toxic-metabolic encephalopathy in children", section on 'Reye syndrome'.)

Physical and occupational therapy can be initiated if required to maintain or improve function.

Limited role of glucocorticoids — In general, we avoid glucocorticoids, which may mask the disease and worsen underlying infection. However, we suggest short courses of glucocorticoids (eg, prednisone up to 15 mg daily followed by a rapid taper over a week) for patients with debilitating symptoms. It should be noted that caution must be used for HIV patients in whom a trial of prednisone for arthritis management is being considered, as many antiretroviral regimens have significant drug interactions with glucocorticoids.

Treatment of the underlying cause — When a specific etiology of viral infection is identified, the decision to initiate antiviral therapy is generally driven by considerations other than the presence of arthritis. Most viruses associated with viral arthritis lack specific therapies. Management of the treatable viral causes of arthritis are discussed in detail separately. (See "Hepatitis B virus: Overview of management" and "Overview of the management of chronic hepatitis C virus infection" and "Acute and early HIV infection: Treatment".)

Treatment of the underlying infection should lead to resolution of the viral arthritis after several weeks. However, there are reports of persistent rheumatic syndromes following eradication of an underlying viral infection [99-101]. In these cases, patients are often treated with the same immunosuppressive drugs used for idiopathic rheumatic diseases, although the efficacy of this approach for chronic viral arthritis is unclear. (See "General principles and overview of management of rheumatoid arthritis in adults" and "General principles and overview of management of rheumatoid arthritis in adults", section on 'Pharmacologic therapy'.)

Specific treatment considerations for specific viral infections are discussed elsewhere.

SUMMARY AND RECOMMENDATIONS

Causes – A wide variety of viral infections can cause arthritis (table 1). Because of changing epidemiology, hepatitis viruses and HIV are less common causes of viral arthritis, whereas other infections, including Zika and chikungunya viruses, are becoming more important. In adults, parvovirus B19 is particularly important to consider, since its presentation may be confused with rheumatoid arthritis. (See 'Causes' above.)

Clinical features – Common clinical features include sudden onset polyarthritis of self-limited duration with concomitant fever, constitutional symptoms, exanthem, or other extraarticular features of systemic infection. In some cases, arthritis may precede other clinical manifestations. (See 'Common clinical features' above.)

Evaluation and diagnosis – The likelihood of a viral etiology depends on the time course of symptoms (algorithm 1):

Acute arthritis – Among patients with acute arthritis (eg, less than four weeks), we suspect a viral etiology in those with polyarthritis associated with recent travel, potential exposure to viral infections, or extraarticular symptoms. Certain such features may suggest specific viral etiologies (eg, a migratory arthritis with hepatitis B infection and rubella). Acute monoarthritis is rarely caused by viral infection and should prompt evaluation for alternative causes.

Because viral arthritis is typically self-limited, extensive testing to establish the viral etiology is generally not indicated, and the diagnosis is made presumptively on the above clinical features and is supported by resolution within a few weeks. When specific testing for viruses is performed (eg, for public health reasons or to screen for HIV or viral hepatitis), acute arthritis can generally be attributed to the detected infection, particularly if it resolves spontaneously or with treatment of the infection. (See 'Acute arthritis' above.)

Chronic arthritis – With the exception of chikungunya virus, viral infection rarely leads to a chronic arthritis, so patients who have arthritis that lasts longer than six weeks should be evaluated for other causes (table 2), including rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritis, and juvenile idiopathic arthritis. (See 'Chronic arthritis' above and 'Differential diagnosis' above.)

The evaluation of chronic polyarthritis is discussed in detail elsewhere. (See "Evaluation of the adult with polyarticular pain".)

ManagementAcetaminophen and nonsteroidal antiinflammatory drugs (NSAIDs) are generally sufficient for symptomatic treatment (table 4). For patients with debilitating symptoms, we suggest a short course of glucocorticoids (Grade 2C). Glucocorticoids may provide faster relief of symptoms; however, they may exacerbate an underlying infection and we thus reserve them for severe cases. Most viral causes of arthritis have no specific management; for those that do, treatment of the underlying infection is associated with resolution of arthritis. (See 'Management' above.)

  1. Kujala G, Newman JH. Isolation of echovirus type 11 from synovial fluid in acute monocytic arthritis. Arthritis Rheum 1985; 28:98.
  2. Blotzer JW, Myers AR. Echovirus-associated polyarthritis. Report of a case with synovial fluid and synovial histologic characterization. Arthritis Rheum 1978; 21:978.
  3. Hurst NP, Martynoga AG, Nuki G, et al. Coxsackie B infection and arthritis. Br Med J (Clin Res Ed) 1983; 286:605.
  4. Naides SJ, Schnitzer TJ. Viral arthritis. In: Textbook of Rheumatology, Kelley WN, Harris ED, Budd RC, et al (Eds), WB Saunders, 2005.
  5. Pennisi E. Genes, junctions, and disease at cell biology meeting. Science 1996; 274:2008.
  6. Oldstone MBA, Notkins AL. Molecular mimicry. In: Concepts in Viral Pathogenesis II, Notkins AL, Oldstone MBA (Eds), Springer-Verlag, 1986.
  7. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999; 341:2068.
  8. Ramos-Casals M. Viruses and lupus: The viral hypothesis. Lupus 2008; 17:163.
  9. Khasnis AA, Schoen RT, Calabrese LH. Emerging viral infections in rheumatic diseases. Semin Arthritis Rheum 2011; 41:236.
  10. Vassilopoulous D, Calabrese LH. Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations. Arthritis Res Ther 2008; 10.
  11. Nesher G, Osborn TG, Moore TL. Parvovirus infection mimicking systemic lupus erythematosus. Semin Arthritis Rheum 1995; 24:297.
  12. Moore TL, Bandlamudi R, Alam SM, Nesher G. Parvovirus infection mimicking systemic lupus erythematosus in a pediatric population. Semin Arthritis Rheum 1999; 28:314.
  13. Moore TL. Parvovirus-associated arthritis. Curr Opin Rheumatol 2000; 12:289.
  14. Assunção-Miranda I, Cruz-Oliveira C, Da Poian AT. Molecular mechanisms involved in the pathogenesis of alphavirus-induced arthritis. Biomed Res Int 2013; 2013:973516.
  15. Gould EA, Coutard B, Malet H, et al. Understanding the alphaviruses: recent research on important emerging pathogens and progress towards their control. Antiviral Res 2010; 87:111.
  16. Suhrbier A, La Linn M. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol 2004; 16:374.
  17. Toivanen A. Alphaviruses: an emerging cause of arthritis? Curr Opin Rheumatol 2008; 20:486.
  18. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 2010; 184:5914.
  19. Morens DM, Fauci AS. Chikungunya at the door--déjà vu all over again? N Engl J Med 2014; 371:885.
  20. Pan American Health Organization, World Health Organization. Chikungunya. https://www.paho.org/en/topics/chikungunya (Accessed on July 21, 2014).
  21. Fischer M, Staples JE, Arboviral Diseases Branch, National Center for Emerging and Zoonotic Infectious Diseases, CDC. Notes from the field: chikungunya virus spreads in the Americas - Caribbean and South America, 2013-2014. MMWR Morb Mortal Wkly Rep 2014; 63:500.
  22. Centers for Disease Control and Prevention. Chikungunya virus in the United States. https://www.cdc.gov/chikungunya/geo/chikungunya-in-the-us.html (Accessed on July 18, 2014).
  23. Adouchief S, Smura T, Sane J, et al. Sindbis virus as a human pathogen-epidemiology, clinical picture and pathogenesis. Rev Med Virol 2016; 26:221.
  24. Acosta-Ampudia Y, Monsalve DM, Rodríguez Y, et al. Mayaro: an emerging viral threat? Emerg Microbes Infect 2018; 7:163.
  25. Kiwanuka N, Sanders EJ, Rwaguma EB, et al. O'nyong-nyong fever in south-central Uganda, 1996-1997: clinical features and validation of a clinical case definition for surveillance purposes. Clin Infect Dis 1999; 29:1243.
  26. Calabrese LH. Emerging viral infections and arthritis: the role of the rheumatologist. Nat Clin Pract Rheumatol 2008; 4:2.
  27. ROBINSON MC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Trans R Soc Trop Med Hyg 1955; 49:28.
  28. Bodenmann P, Genton B. Chikungunya: an epidemic in real time. Lancet 2006; 368:258.
  29. Johnston REPC. Alphaviruses. In: Virology, Third Edition, Fields BN, Knipe DM, Howley PM, et al (Eds), Lippincott-Raven, 1996. p.843.
  30. Mylonas AD, Brown AM, Carthew TL, et al. Natural history of Ross River virus-induced epidemic polyarthritis. Med J Aust 2002; 177:356.
  31. Brighton SW, Prozesky OW, de la Harpe AL. Chikungunya virus infection. A retrospective study of 107 cases. S Afr Med J 1983; 63:313.
  32. Shuaib W, Stanazai H, Abazid AG, Mattar AA. Re-Emergence of Zika Virus: A Review on Pathogenesis, Clinical Manifestations, Diagnosis, Treatment, and Prevention. Am J Med 2016; 129:879.e7.
  33. Rigau-Pérez JG. The early use of break-bone fever (Quebranta huesos, 1771) and dengue (1801) in Spanish. Am J Trop Med Hyg 1998; 59:272.
  34. Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313.
  35. Schmidt AC. Response to dengue fever--the good, the bad, and the ugly? N Engl J Med 2010; 363:484.
  36. Inman RD, Hodge M, Johnston ME, et al. Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection. Ann Intern Med 1986; 105:700.
  37. Hsu HH, Feinstone SM, Houfnagle JH. Acute viral hepatitis. In: Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases, Fourth Edition, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, 1995. p.1100.
  38. Sharma V, Sharma A. Infectious mimics of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2022; 36:101736.
  39. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004; 350:1118.
  40. Alarcon GS, Townes AS. Arthritis in viral hepatitis. Report of two cases and review of the literature. Johns Hopkins Med J 1973; 132:1.
  41. Wands JR, Mann E, Alpert E, Isselbacher KJ. The pathogenesis of arthritis associated with acute hepatitis-B surface antigen-positive hepatitis. Complement activation and characterization of circulating immune complexes. J Clin Invest 1975; 55:930.
  42. Shumaker JB, Goldfinger SE, Alpert E, Isselbacher KJ. Arthritis and rash. Clues to anicteric viral hepatitis. Arch Intern Med 1974; 133:483.
  43. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: Clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37:663.
  44. Levo Y, Gorevic PD, Kassab HJ, et al. Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med 1977; 296:1501.
  45. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46 Suppl 5:S165.
  46. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995; 122:169.
  47. Rivera J, García-Monforte A, Pineda A, Millán Núñez-Cortés J. Arthritis in patients with chronic hepatitis C virus infection. J Rheumatol 1999; 26:420.
  48. Smith CA, Petty RE, Tingle AJ. Rubella virus and arthritis. Rheum Dis Clin North Am 1987; 13:265.
  49. Ogra PL, Herd JK. Arthritis associated with induced rubella infection. J Immunol 1971; 107:810.
  50. Ray P, Black S, Shinefield H, et al. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA 1997; 278:551.
  51. Slater PE. Chronic arthropathy after rubella vaccination in women. False alarm? JAMA 1997; 278:594.
  52. American Academy of Pediatrics. Rubella. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.648.
  53. Spruance SL, Metcalf R, Smith CB, et al. Chronic arthropathy associated with rubella vaccination. Arthritis Rheum 1977; 20:741.
  54. Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47:1.
  55. Mitchell LA, Tingle AJ, Grace M, et al. Rubella virus vaccine associated arthropathy in postpartum immunized women: influence of preimmunization serologic status on development of joint manifestations. J Rheumatol 2000; 27:418.
  56. Chantler JK, Tingle AJ, Petty RE. Persistent rubella virus infection associated with chronic arthritis in children. N Engl J Med 1985; 313:1117.
  57. Fraser JR, Cunningham AL, Hayes K, et al. Rubella arthritis in adults. Isolation of virus, cytology and other aspects of the synovial reaction. Clin Exp Rheumatol 1983; 1:287.
  58. Ford DK, da Roza DM, Reid GD, et al. Synovial mononuclear cell responses to rubella antigen in rheumatoid arthritis and unexplained persistent knee arthritis. J Rheumatol 1982; 9:420.
  59. Weibel RE, Stokes J Jr, Buynak EB, Hilleman MR. Rubella vaccination in adult females. N Engl J Med 1969; 280:682.
  60. Chantler JK, da Roza DM, Bonnie ME, et al. Sequential studies on synovial lymphocyte stimulation by rubella antigen, and rubella virus isolation in an adult with persistent arthritis. Ann Rheum Dis 1985; 44:564.
  61. Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr Opin Rheumatol 2009; 21:404.
  62. Reveille JD. The changing spectrum of rheumatic disease in human immunodeficiency virus infection. Semin Arthritis Rheum 2000; 30:147.
  63. Walker-Bone K, Doherty E, Sanyal K, Churchill D. Assessment and management of musculoskeletal disorders among patients living with HIV. Rheumatology (Oxford) 2017; 56:1648.
  64. Adizie T, Moots RJ, Hodkinson B, et al. Inflammatory arthritis in HIV positive patients: A practical guide. BMC Infect Dis 2016; 16:100.
  65. Cooper DA, Gold J, Maclean P, et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet 1985; 1:537.
  66. Rynes RI, Goldenberg DL, DiGiacomo R, et al. Acquired immunodeficiency syndrome-associated arthritis. Am J Med 1988; 84:810.
  67. Berman A, Cahn P, Perez H, et al. Human immunodeficiency virus infection associated arthritis: clinical characteristics. J Rheumatol 1999; 26:1158.
  68. Fox C, Walker-Bone K. Evolving spectrum of HIV-associated rheumatic syndromes. Best Pract Res Clin Rheumatol 2015; 29:244.
  69. Winchester R, Bernstein DH, Fischer HD, et al. The co-occurrence of Reiter's syndrome and acquired immunodeficiency. Ann Intern Med 1987; 106:19.
  70. Cuellar ML, Espinoza LR. Rheumatic manifestations of HIV-AIDS. Baillieres Best Pract Res Clin Rheumatol 2000; 14:579.
  71. Brancato L, Itescu S, Skovron ML, et al. Aspects of the spectrum, prevalence and disease susceptibility determinants of Reiter's syndrome and related disorders associated with HIV infection. Rheumatol Int 1989; 9:137.
  72. Solomon G, Brancato L, Winchester R. An approach to the human immunodeficiency virus-positive patient with a spondyloarthropathic disease. Rheum Dis Clin North Am 1991; 17:43.
  73. Njobvu P, McGill P. Human immunodeficiency virus related reactive arthritis in Zambia. J Rheumatol 2005; 32:1299.
  74. López-Larrea C, Njobvu PD, González S, et al. The HLA-B*5703 allele confers susceptibility to the development of spondylarthropathies in Zambian human immunodeficiency virus-infected patients with slow progression to acquired immunodeficiency syndrome. Arthritis Rheum 2005; 52:275.
  75. Maganti RM, Reveille JD, Williams FM. Therapy insight: the changing spectrum of rheumatic disease in HIV infection. Nat Clin Pract Rheumatol 2008; 4:428.
  76. Reveille JD, Conant MA, Duvic M. Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and Reiter's syndrome: a disease continuum? Arthritis Rheum 1990; 33:1574.
  77. Calabrese LH, Naides SJ. Viral arthritis. Infect Dis Clin North Am 2005; 19:963.
  78. Naides SJ. Viral arthritis. In: Kelley's Textbook of Rheumatology, Seventh Edition, Harris ED, Budd RC, Genovese MC, et al (Eds), Elseveier-Saunder, 2005. p.1688.
  79. Gordon SC, Lauter CB. Mumps arthritis: a review of the literature. Rev Infect Dis 1984; 6:338.
  80. Fraser KJ, Clarris BJ, Muirden KD, et al. A persistent adenovirus type 1 infection in synovial tissue from an immunodeficient patient with chronic, rheumatoid-like polyarthritis. Arthritis Rheum 1985; 28:455.
  81. Sigal LH, Steere AC, Niederman JC. Symmetric polyarthritis associated with heterophile-negative infectious mononucleosis. Arthritis Rheum 1983; 26:553.
  82. Gilliam BE, Reed MR, Syed RH, Moore TL. Rheumatic manifestations of Epstein-Barr virus in children. J Pediatr Infect Dis 2009; 4:333.
  83. Callan MF. Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. Curr Opin Rheumatol 2004; 16:399.
  84. Fierman AH. Varicella-associated arthritis occurring before the exanthem. Case report and literature review. Clin Pediatr (Phila) 1990; 29:188.
  85. Pascual-Gómez E. Identification of large mononuclear cells in varicella arthritis. Arthritis Rheum 1980; 23:519.
  86. Friedman HM, Pincus T, Gibilisco P, et al. Acute monoarticular arthritis caused by herpes simplex virus and cytomegalovirus. Am J Med 1980; 69:241.
  87. Remafedi G, Muldoon RL. Acute monarticular arthritis caused by herpes simplex virus type I. Pediatrics 1983; 72:882.
  88. Fiala M, Payne JE, Berne TV, et al. Epidemiology of cytomegalovirus infection after transplantation and immunosuppression. J Infect Dis 1975; 132:421.
  89. Rubin RH. Clinical approach to infection in the compromised host. In: Infection in the organ transplant recipient, First Edition, Rubin RH, Young NS (Eds), Kluwer Academic Press, 2002. p.573.
  90. Sinaei R, Pezeshki S, Parvaresh S, et al. Post SARS-CoV-2 infection reactive arthritis: a brief report of two pediatric cases. Pediatr Rheumatol Online J 2021; 19:89.
  91. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol 2021; 73:e13.
  92. Zeichhardt H, Grunert HP. Enteroviruses. In: Infectious Disease Textbook, First Edition, Armstrong D, Cohen J (Eds), Mosby, 1999. p.8212.
  93. Krijbolder DI, Khidir SJH, Matthijssen XME, et al. Hand function is already reduced before RA development and reflects subclinical tenosynovitis. RMD Open 2023; 9.
  94. Li C, Li H, Yang X, et al. Meta-analysis of synovial fluid polymerase chain reaction for diagnosing periprosthetic hip and knee infection. J Orthop Surg Res 2022; 17:3.
  95. Stahl HD, Hubner B, Seidl B, et al. Detection of multiple viral DNA species in synovial tissue and fluid of patients with early arthritis. Ann Rheum Dis 2000; 59:342.
  96. Chang AY, Martins KAO, Encinales L, et al. Chikungunya Arthritis Mechanisms in the Americas: A Cross-Sectional Analysis of Chikungunya Arthritis Patients Twenty-Two Months After Infection Demonstrating No Detectable Viral Persistence in Synovial Fluid. Arthritis Rheumatol 2018; 70:585.
  97. Chang AY, Encinales L, Porras A, et al. Frequency of Chronic Joint Pain Following Chikungunya Virus Infection: A Colombian Cohort Study. Arthritis Rheumatol 2018; 70:578.
  98. Zaid A, Gérardin P, Taylor A, et al. Chikungunya Arthritis: Implications of Acute and Chronic Inflammation Mechanisms on Disease Management. Arthritis Rheumatol 2018; 70:484.
  99. Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N. Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology 2017; 65:1770.
  100. Levine JW, Gota C, Fessler BJ, et al. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005; 32:1164.
  101. Gragnani L, Lorini S, Marri S, et al. Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life. Autoimmun Rev 2022; 21:102923.
Topic 5614 Version 22.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟